Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Inclusion Criteria:

1. Age ≥18 years;

2. Patients with relapsed/refractory marginal zone lymphoma or follicular lymphoma

3. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-2;

4. At least one measurable lesion by computerised tomography (CT) / magnetic resonanceimaging (MRI) (the longest diameter of nodal lesion > 1.5 cm or extranodal lesion > 1 cm);

5. Expected survival of more than 12 weeks;

Exclusion Criteria:

1. Having lymphoma with central nervous system (CNS) or cerebral pia mater invasion;

2. Known histologic transformation to aggressive lymphomas such as diffuse large B-celllymphoma (DLBCL);

3. Prior use of any phosphatidylinositol 3-kinase (PI3K) inhibitor;

4. Inadequate organ function of liver and kidney;

5. Currently known active infection with human immunodeficiency virus (HIV), hepatitisB virus (HBV) or hepatitis C virus (HCV);

6. Having received systemic antitumor therapy or radiotherapy within 4 weeks prior tothe first dose of the investigational product;

7. Toxicity of previous antitumor therapy not recovered to CTCAE grade ≤ 1, exceptalopecia, prior to the first dose of the investigational product;

8. Complicated with uncontrolled systemic infection requiring intravenous antibiotictreatment;

9. Pregnant (positive serum pregnancy test) or lactating women;

10. Any other disease, metabolic abnormality, physical examination abnormality orclinically significant laboratory test abnormality, one disease or state providing areason to suspect that the subject is not suitable for HMPL-689 at theinvestigator's discretion, or one condition that will affect interpretation of thestudy results or bring the subject at high risk.